University Of Antwerp — Clinical Trial Site

25 Registered trials

4 Currently recruiting

Organisation

University Of Antwerp

Location

Edegem, Belgium

Identifier

ORG-100007985

Address

Universiteitsplein 1, 2610, Belgium

Departments

BE005: Vaccinopolis Centrum voor de Evaluatie van Vaccinaties
Center for Evaluation of Vaccination
Center for Evaluation of Vaccination (CEV)
Centre for Evaluation of Vaccination (CEV)
Centre for the Evaluation of Vaccination
Centre of Evaluation of Vaccination
Centrum voor de Evaluatie van Vaccinaties (CEV)
CEV - entrum voor de Evaluatie van Vaccinatie (Vaccinopolis)
Gastroenterology
Gastroenterology/Hepatology
Hematology
Kinderoncologie en kinderhematologie
Neurology
Oncology
Pediatry
Pneumology
Thoracic Oncology
Vaccin & Infectieziekten Instituut
Vaccination
Vaccine & infectious disease institute
VAXINFECTIO

Clinical trials at this site (25)

Search interface

GBS-NN/NN2 (50 μg of each fusion protein [GBS-NN and GBS-NN2] in combination with 500 μg Aluminum as Alhydrogel®) given with and without the… Pending

2023-508563-73-00 Prevention of Group B streptococcus infection 10
A study to evaluate the efficacy, immunogenicity, and safety of an RSV and hMPV VLP vaccine compared with placebo in participants aged 60 ye… Pending

2024-513740-28-00 Respiratory Syncytial Virus and Human Metapneumovirus 5
The optimal timing of vaccination in pregnancy: a multi-dimensional mechanistic approach to measure immune responses in pregnant women (MATI… Pending

2024-518692-56-00 Pregnant 6
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease Pending

2025-521113-13-00 Early Parkinson’s Disease 10
A study on the safety of and immune response to different doses of RSV/hMPV combination and hMPV vaccines in adults Pending

2025-524456-58-00 Respiratory Syncytial Virus Infections+Metapneumovirus 7
A Phase 2 Platform Study to Evaluate Therapies for Inflammatory Bowel Disease Recruiting

2025-522001-38-00 Crohn’s Disease 4 2026-05-27
Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Previously Untreated, Unresectable, or Met… Recruiting

2025-523224-45-00 Untreated, Unresectable or Metastatic Colorectal Cancer 10 2026-03-30
The PEARL trial: Prevention of hepatic Encephalopathy by administration of Rifaximin and Lactulose in patients with liver cirrhosis undergoi… Recruiting

2024-512040-28-01 Confirmed diagnosis of Alcoholic liver cirrhosis 6 2026-03-01
HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t… Recruiting

2024-514917-36-00 Patients with High Risk Neuroblastoma 5 2024-11-21
A Phase 3 Study to Assess the Safety and Immunogenicity of High-dose Influenza Vaccine in Adults ≥ 60 years of Age Ended

2024-519743-15-00 Influenza immunisation 5 2025-10-20
A Phase I/IIa Study of Roginolisib in combination with dostarlimab with or without docetaxel in Advanced NSCLC (PULMO-01) Ended

2024-517741-14-00 advanced non-squamous non-small cell lung cancer (NSCLC 9 2025-04-22
An extension and crossover vaccination study on the immune response and safety of a vaccine against respiratory syncytial virus given to adu… Ended

2023-509762-38-00 Respiratory Syncytial Virus Infections 5 2024-08-01
PH2a, Platform Study of Novel Immunotherapy Combinations in Participants with Previously Untreated, Advanced/Metastatic NSCLC Ended

2023-505057-40-00 Lung Cancer, Non-Small Cell 4 2022-12-02
Efficacy, immunogenicity, and safety of the 9vHPV vaccine in adult males 20 to 45 years of age Ended

2022-501974-21-00 Prevention of oral persistent infection caused by any o 5 2020-04-01
Phase IV multicenter trial to evaluate the immunogenicity and safety of the Seqirus licensed zoonotic influenza vaccine (H5N8) in adults pre… Ended

2025-522116-16-00 Avian Influenza 6 2025-12-08
A study to assess the immune response and safety of a vaccine against influenza in adults 18 years of age and older Ended

2025-522599-97-00 Influenza, Human 4 2025-10-30
Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, immunogenicity and safety of one dose of… Ended

2024-520354-37-00 Influenza disease 4 2025-09-08
A phase 4, open-label study to evaluate the short-term innate immune response after administration of a COVID-19 mRNA vaccine (Comirnaty JN… Ended

2024-520304-26-00 COVID-19 6 2025-05-05
A Study to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Influenza Vaccine Compared with a Licensed Influenza … Ended

2024-516240-26-00 Influenza 5 2024-10-11
A Phase I, randomized, double-blind, multi-centre, placebo-controlled, dose-escalation study to evaluate the safety, reactogenicity and immu… Ended

2024-511194-29-00 Yellow fever 1 2024-06-16
SAFE study: Stopping Antibiotics after 3 days for the treatment of FEbrile Neutropenia in Haematology patients, a randomized open-label non-… Ended

2022-500389-84-00 Febrile neutropenia 6 2024-02-16
A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadr… Ended

2023-504168-40-00 Prevention of invasive extraintestinal pathogenic Esche 5 2023-11-06
A study to find and confirm the dose and assess the safety, reactogenicity and immune response of a vaccine against influenza in healthy you… Ended

2022-502308-66-00 Healthy volunteers (prevention of influenza infection) 7 2023-04-27
Safety and Efficacy study assessing Pegunigalsidase Alfa (PRX-102) Administered by Intravenous Infusion Every 4 Weeks in Patients With Fabry… Ended

2024-516735-27-00 Fabry disease (α-galactosidase A deficiency) 5 2019-01-31